PharmaEssentia
Update in progress6446.TW (Taiwan)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
PharmaEssentia Corporation is a biopharmaceutical company focused on medicine discovery and developing specialty pharmaceutical reagents, active pharmaceutical ingredients (API), and new drug candidates for markets in the Americas, Europe, Asia and Taiwan. Its product BESREMi is an interferon therapy for polycythemia vera, essential thrombocythemia, myelofibrosis and adult T-cell leukemia. The company also advances Ropeg + anti-PD-1, PEG-IL-2 (P11838), PEG-Cytokines, PD-1-IL-2v, ADCs, NY-ESO-1 TCR-T and novel TCR-T approaches for solid tumors and immunology. Founded 1990, headquartered in Taipei.
Company score
- Sentiment
- 0.33
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.02
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.10
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.21
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketTaiwan (TAI)
- LocationTaiwan
- CEOMr. Ko-Chung Lin Ph.D.
- Founded1990
- Websitewww.pharmaessentia.com
Identifiers
- ISINTW0006446008